INmune Bio Investor Relations Material
Latest events
Q2 2025
INmune Bio
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from INmune Bio Inc
Access all reports
INmune Bio, Inc. is a clinical-stage immunotherapy company. The company focuses on reprogramming the patient's innate immune system to treat cancer, Alzheimer's disease and non-alcoholic steatohepatitis. It has several development programs, including INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation in their blood; XPro1595 for the treatment of Alzheimer's disease; LivNate to treat patients with non-alcoholic steatohepatitis; and Quellor for cytokine release syndrome and complications of COVID-19
Key slides for INmune Bio Inc
Corporate Presentation
INmune Bio Inc
Corporate Presentation
INmune Bio Inc
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
INMB
Country
🇺🇸 United States